HUE036214T2 - Eljárások aripiprazol-szuszpenzió és fagyasztva szárított készítmény elõállítására - Google Patents

Eljárások aripiprazol-szuszpenzió és fagyasztva szárított készítmény elõállítására

Info

Publication number
HUE036214T2
HUE036214T2 HUE08792242A HUE08792242A HUE036214T2 HU E036214 T2 HUE036214 T2 HU E036214T2 HU E08792242 A HUE08792242 A HU E08792242A HU E08792242 A HUE08792242 A HU E08792242A HU E036214 T2 HUE036214 T2 HU E036214T2
Authority
HU
Hungary
Prior art keywords
freeze
preparing
methods
dried preparation
aripiprazole suspension
Prior art date
Application number
HUE08792242A
Other languages
English (en)
Hungarian (hu)
Inventor
Shogo Hiraoka
Takakuni Matsuda
Junichi Hatanaka
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39816777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE036214(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HUE036214T2 publication Critical patent/HUE036214T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HUE08792242A 2007-07-31 2008-07-30 Eljárások aripiprazol-szuszpenzió és fagyasztva szárított készítmény elõállítására HUE036214T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007200088 2007-07-31

Publications (1)

Publication Number Publication Date
HUE036214T2 true HUE036214T2 (hu) 2018-06-28

Family

ID=39816777

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08792242A HUE036214T2 (hu) 2007-07-31 2008-07-30 Eljárások aripiprazol-szuszpenzió és fagyasztva szárított készítmény elõállítására

Country Status (27)

Country Link
US (7) US9457026B2 (esLanguage)
EP (1) EP2170279B1 (esLanguage)
JP (1) JP4879349B2 (esLanguage)
KR (1) KR101546106B1 (esLanguage)
CN (1) CN101801342B (esLanguage)
AR (2) AR067747A1 (esLanguage)
CA (1) CA2695178C (esLanguage)
CO (1) CO6290634A2 (esLanguage)
CY (1) CY1120165T1 (esLanguage)
DK (1) DK2170279T3 (esLanguage)
ES (1) ES2661037T3 (esLanguage)
HR (1) HRP20180295T1 (esLanguage)
HU (1) HUE036214T2 (esLanguage)
IL (2) IL244186A0 (esLanguage)
LT (1) LT2170279T (esLanguage)
MX (1) MX2010001311A (esLanguage)
MY (1) MY152789A (esLanguage)
NO (1) NO2170279T3 (esLanguage)
NZ (1) NZ582415A (esLanguage)
PL (1) PL2170279T3 (esLanguage)
PT (1) PT2170279T (esLanguage)
RU (1) RU2483711C2 (esLanguage)
SI (1) SI2170279T1 (esLanguage)
TW (1) TWI410255B (esLanguage)
UA (1) UA97286C2 (esLanguage)
WO (1) WO2009017250A1 (esLanguage)
ZA (1) ZA201000307B (esLanguage)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2170279T (lt) * 2007-07-31 2018-03-12 Otsuka Pharmaceutical Co., Ltd. Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
JP5575269B2 (ja) * 2010-08-24 2014-08-20 大塚製薬株式会社 カルボスチリル誘導体並びにシリコーンオイル及び／又はシリコーンオイル誘導体を含有する懸濁液及びケーキ組成物
CN105125509B (zh) * 2011-01-24 2019-01-11 大塚制药株式会社 以阿立哌唑作为有效成分的块状组合物
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
KR101103011B1 (ko) * 2011-10-13 2012-01-05 (주)일신오토클레이브 스크루 형 고압 발생 장치
CN102524261B (zh) * 2011-12-16 2014-12-03 辽宁师范大学 一种强力生根剂纳米制剂、其制备方法及应用
CN102450269A (zh) * 2011-12-27 2012-05-16 辽宁师范大学 三唑酮纳米胶体悬浮剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
US9655951B2 (en) * 2013-01-23 2017-05-23 Cartilast II LLC Preservation of the biological activity of undenatured type II collagen
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
EP3233077B1 (en) 2014-12-19 2026-05-06 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2017025930A1 (en) 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
CN106474058B (zh) * 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
US20190160002A1 (en) 2016-07-28 2019-05-30 Mylan Laboratories Limited Process for preparing sterile aripiprazole formulation
US10821200B2 (en) * 2016-12-05 2020-11-03 Hyalo Technologies, LLC Method of sterilization of microparticles
CN108938578A (zh) * 2017-05-25 2018-12-07 万全万特制药（厦门）有限公司 阿立哌唑分散片及其制备方法
WO2021199076A1 (en) * 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
CN115364049B (zh) * 2021-05-18 2026-04-10 苏州恩华生物医药科技有限公司 一种月桂酰阿立哌唑混悬剂的制备方法
JP2024016759A (ja) * 2022-07-26 2024-02-07 ニプロ株式会社 アリピプラゾール懸濁液の製造方法
CN115554253B (zh) * 2022-10-14 2024-03-29 浙江圣兆药物科技股份有限公司 一种平稳释药的注射用阿立哌唑冻干制剂及其制备方法
CN117281784B (zh) * 2023-11-24 2024-02-27 山东则正医药技术有限公司 一种阿立哌唑注射剂及其制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209551A (en) 1922-11-20 1924-01-17 William Mortimer Melmore Improvements in or relating to petrol and other cans
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
CA1209477A (en) 1981-03-26 1986-08-12 Bruce E. Haeger Composition of matter comprising a lyophilized preparation of a penicillin derivative
JPS5832899A (ja) * 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
IL68549A (en) * 1983-05-03 1988-05-31 Kit Medidont Ltd Method and instrument for measuring moisture
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
IT1244880B (it) 1990-12-11 1994-09-12 Torre A Farmaceutici Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
JP4142095B2 (ja) 1994-06-02 2008-08-27 クアドラント・ドラツグ・デリバリー・リミテツド 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
RU2082401C1 (ru) 1994-08-18 1997-06-27 Фармацевтическое акционерное общество "Ферейн" Способ получения лекарственной формы комбинированного препарата
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6165442A (en) * 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
EP0941066B1 (en) 1996-08-26 2003-10-29 Transgene S.A. Cationic lipid-nucleic acid complexes
US6297231B1 (en) * 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
AU761205B2 (en) * 1998-03-30 2003-05-29 Skyepharma Canada Inc. Composition and method of preparing microparticles of water-insoluble substances
ATE355856T1 (de) * 1998-07-30 2007-03-15 Point Biomedical Corp Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
AU5170400A (en) * 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
JP2001187735A (ja) 2000-01-05 2001-07-10 Towa Yakuhin Kk 安定なニコランジル含有粉末の製造法
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
RU2169574C1 (ru) 2000-01-27 2001-06-27 Кобатов Алексей Иванович Способ получения биопрепарата и сухой биопрепарат
WO2001058428A1 (en) 2000-02-10 2001-08-16 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
CN1229339C (zh) 2000-03-27 2005-11-30 斯克里普斯研究学院 抑制血管生成和肿瘤生长的化合物，含有该化合物的药用制剂，以及该化合物的制药用途
AU2001257115B2 (en) 2000-04-20 2005-01-27 Rtp Pharma Inc. Improved water-insoluble drug particle process
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002241284A (ja) 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
CN100350977C (zh) 2001-06-14 2007-11-28 大塚制药株式会社 药物组合物
US20050019399A1 (en) 2001-09-21 2005-01-27 Gina Fischer Controlled release solid dispersions
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ITMI20020808A1 (it) * 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
NZ537995A (en) * 2002-08-20 2007-11-30 Bristol Myers Squibb Co Inclusion complex of aripiprazole in a substituted b-cyclodextrin
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
HUP0500846A3 (en) * 2002-12-31 2008-10-28 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent for pulmonary administration
US7658998B2 (en) 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
JP2005022989A (ja) 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
CA2543296A1 (en) * 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
WO2005072702A2 (en) * 2004-01-20 2005-08-11 Alkermes Controlled Therapeutics, Inc. Method for milling frozen microparticles
CA2559915C (en) * 2004-03-23 2013-07-02 Novartis Ag Micronization of pharmaceutically active agents
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
CA2600541C (en) * 2005-03-17 2018-01-09 Synthon B.V. Process of making crystalline type ii aripiprazole
WO2007035348A2 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US9034381B2 (en) * 2005-11-10 2015-05-19 Alphapharm Pty Ltd Process to control particle size
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
LT2170279T (lt) * 2007-07-31 2018-03-12 Otsuka Pharmaceutical Co., Ltd. Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai

Also Published As

Publication number Publication date
LT2170279T (lt) 2018-03-12
IL244186A0 (en) 2016-04-21
TW200922636A (en) 2009-06-01
RU2483711C2 (ru) 2013-06-10
ZA201000307B (en) 2011-04-28
US20200246333A1 (en) 2020-08-06
MY152789A (en) 2014-11-28
WO2009017250A1 (en) 2009-02-05
ES2661037T3 (es) 2018-03-27
AU2008283251A1 (en) 2009-02-05
KR101546106B1 (ko) 2015-08-20
US20250302826A1 (en) 2025-10-02
HRP20180295T1 (hr) 2018-03-23
US20210361646A1 (en) 2021-11-25
PL2170279T3 (pl) 2018-05-30
CA2695178C (en) 2015-06-23
TWI410255B (zh) 2013-10-01
US20100196486A1 (en) 2010-08-05
AR117941A2 (es) 2021-09-08
CN101801342B (zh) 2012-07-11
DK2170279T3 (en) 2018-03-12
JP4879349B2 (ja) 2012-02-22
MX2010001311A (es) 2010-04-21
BRPI0815382A2 (pt) 2015-02-10
US9457026B2 (en) 2016-10-04
JP2010535151A (ja) 2010-11-18
PT2170279T (pt) 2018-04-06
EP2170279A1 (en) 2010-04-07
UA97286C2 (ru) 2012-01-25
CO6290634A2 (es) 2011-06-20
IL244231A0 (en) 2016-04-21
US20170035752A1 (en) 2017-02-09
RU2009149820A (ru) 2011-09-10
US20240139177A1 (en) 2024-05-02
EP2170279B1 (en) 2017-12-27
NO2170279T3 (esLanguage) 2018-05-26
KR20100057020A (ko) 2010-05-28
CA2695178A1 (en) 2009-02-05
SI2170279T1 (en) 2018-04-30
US20180185358A1 (en) 2018-07-05
CY1120165T1 (el) 2018-12-12
NZ582415A (en) 2012-05-25
CN101801342A (zh) 2010-08-11
AR067747A1 (es) 2009-10-21

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HUS2100009I1 (hu) Halauxifen-metil és piroxszulam kombinációja
PT2170279T (pt) Métodos para produção de suspensão de aripiprazole e formulação liofilizada
IL294095A (en) Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
HUE036439T2 (hu) Antimikrobiális készítmények és azok alkalmazási módszerei
HUS1900012I1 (hu) Vegyületek és készítmények protein-kináz inhibitorokként
HUE051666T2 (hu) Módosított RSV F fehérjék és alkalmazásuk módszerei
HUE041426T2 (hu) Terápiás nukleáz-készítmények és eljárások
HUE053357T2 (hu) Gyógyszerészeti készítmény és annak beadásai
IL241985A0 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
EP2539473B8 (en) Modified proteins and methods of making and using same
HUE044292T2 (hu) Eljárások és készítmények aeroszolok elõállítására
HUE040019T2 (hu) Hajnövekedést stimuláló készítmények és módszerek
HUE049986T2 (hu) Rifaximin készítmények és ezek alkalmazásai
HUE042011T2 (hu) Arilmetoxi-izoindolin-származékok, azok készítményei és alkalmazási módszereik
HUE043040T2 (hu) Poliszacharid keresztkötéseket tartalmazó fehérje készítmény és/vagy formula
HUE036309T2 (hu) Szilícium-dioxid nanoszemcsék és ezek alkalmazása vakcináláshoz
HUE037061T2 (hu) Specifikusan kötõdõ fehérjék és alkalmazásuk
HUE045348T2 (hu) Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
HUE042516T2 (hu) Javított eljárás treprosztinilnek és származékainak elõállítására
HUE036077T2 (hu) Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
CU24123B1 (es) Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato
PT2413924T (pt) Fenil acetato de l-ornitina e métodos de preparação do mesmo
EP2367866A4 (en) POLYESTER, MANUFACTURING METHOD THEREFOR AND USE
IL208241A0 (en) Heat shock protein gp96 vaccination and methods of using same